Next Article in Journal / Special Issue
Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling
Previous Article in Journal / Special Issue
Mammary Development and Breast Cancer: A Wnt Perspective
Article Menu

Export Article

Open AccessReview
Cancers 2016, 8(7), 66; doi:10.3390/cancers8070066

A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers

1
Department of Pharmacology and Toxicology, University of Lausanne, Lausanne 1011, Switzerland
2
School of Biomedicine, Far Eastern Federal University, Vladivostok 690922, Russia
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editors: Renée van Amerongen and Walter Birchmeier
Received: 28 May 2016 / Revised: 24 June 2016 / Accepted: 7 July 2016 / Published: 14 July 2016
(This article belongs to the Special Issue Wnt Signaling in Cancer)
View Full-Text   |   Download PDF [575 KB, uploaded 14 July 2016]   |  

Abstract

Aberrant WNT signaling underlies cancerous transformation and growth in many tissues, such as the colon, breast, liver, and others. Downregulation of the WNT pathway is a desired mode of development of targeted therapies against these cancers. Despite the urgent need, no WNT signaling-directed drugs currently exist, and only very few candidates have reached early phase clinical trials. Among different strategies to develop WNT-targeting anti-cancer therapies, repositioning of existing drugs previously approved for other diseases is a promising approach. Nonsteroidal anti-inflammatory drugs like aspirin, the anti-leprotic clofazimine, and the anti-trypanosomal suramin are among examples of drugs having recently revealed WNT-targeting activities. In total, 16 human-use drug compounds have been found to be working through the WNT pathway and show promise for their prospective repositioning against various cancers. Advances, hurdles, and prospects of developing these molecules as potential drugs against WNT-dependent cancers, as well as approaches for discovering new ones for repositioning, are the foci of the current review. View Full-Text
Keywords: approved drugs; WNT pathway; repositioning approved drugs; WNT pathway; repositioning
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ahmed, K.; Shaw, H.V.; Koval, A.; Katanaev, V.L. A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers. Cancers 2016, 8, 66.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top